Regulus Therapeutics Inc. (RGLS) Financials

RGLS Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 37.7 million 9.5 million
2023-06-30 43.6 million 9.7 million
2023-03-31 37.0 million 10.4 million
2022-12-31 46.7 million 13.4 million

RGLS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -6.8 million 973000
2023-06-30 -6.3 million 382000
2023-03-31 -8.1 million 410000
2022-12-31 -6.3 million 397000

RGLS Net Income

No data available :(

RGLS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 30.8 million - 1.2 million
2023-06-30 37.3 million - 1.4 million
2023-03-31 30.3 million - 1.6 million
2022-12-31 39.2 million - 1.8 million

RGLS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 19.6 million
2023-06-30 19.1 million
2023-03-31 16.8 million
2022-12-31 16.8 million

RGLS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 541000 5.5 million 2.6 million -
2023-06-30 - 5.0 million 2.3 million -
2023-03-31 1000 4.9 million 2.4 million -
2022-12-31 63000 4.7 million 2.2 million -

RGLS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 56000
2023-06-30 - 47000
2023-03-31 - 48000
2022-12-31 - 33000

RGLS

Price: $2.43

52 week price:
0.85
3.79

Earnings Per Share: -1.58 USD

P/E Ratio: -0.89

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 68300

Ebitda: -14.7 million

Market Capitalization: 169.6 million

Links: